Bacterial immunostimulants - Mechanism of action and clinical application in respiratory diseases

Pneumonologia i Alergologia Polska

Volumn 76, Issue 5, 2008, Pages 353-359

  Rozy, Adriana ^a   Chorostowska Wynimko, Joanna ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Bacterial lysate; Immunostimulation; Respiratory tract infections; Ribosomal extracts

Indexed keywords

BACTERIUM LYSATE; CELL EXTRACT; IMMUNOLOGICAL ADJUVANT;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; BACTERIUM; CHILD; DRUG EFFECT; HUMAN; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; BACTERIA; CELL EXTRACTS; CHILD; HUMANS; IMMUNITY, ACTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 57049170370     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lasek W. Immunomodulacja. In: Immunologia. Ed. Goła̧b M., Jakóbisiak M., Lasek W. Wydawnictwo PWN, Warszawa 2002; 482-492.
2. Płusa T. Leczenie szczepionkami przeciwwirusowymi i przeciwbakteryjnymi. Alergol. Wsp. 2000; 1:13-18.
3. Zielnik-Jurkiewicz B., Jurkiewicz D., Stankiewicz W. Skutecznoś ć Broncho-Vaxomu® w zapobieganiu nawracajqcym zakażeniom górnych dróg oddechowych u dzieci. Pol. Merkur. Lek. 2005; 19: 625-629.
4. Grzesiowski P., Hryniewicz W. Immunologia szczepień ochrannych. In: Immunologia. Ed. Goła̧b M., Jakóbisiak M., Lasek W. Wydawnictwo PWN, Warszawa 2002; 356-372.
5. Lasek W. Układ odpornościowy zwia̧zany z błonami śluzowymi. In: Immunologia. Ed. Goła̧b M., Jakóbisiak M., Lasek W. Wydawnictwo PWN, Warszawa 2002; 288-302.
6. Villaroman M.L., Manuel I., Trajera D. et al. Immunomodulators in preventing recurrent respiratory tract infections (RRTI): a meta-analysis. Phil. J. Internal Medicine 2001; 39:193-200.
7. Mauel J., Van Pham T., Kreis B., Bauer J. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int. J. Immunopharmacol. 1989; 11: 637-645.
8. Mierzejewska-Zawisza M.J., Jahnz-Rozyk K., Rabczuk J. Zastosowanie preparatu Broncho-Vaxom w praktyce klinicznej. Pol. Merkur. Lek. 2003; 14: 457-458.
9. Roth M., Keul R., Papakonstantinou E. et al. Characterization of intracellular signaling transduction and transcription factors involved in Broncho-Vaxom (OM-85 BV)-induced expression of interleukin-6 and interleukin-8 in human pulmonary fibro-blasts. Eur. Respir. Rev. 1996; 6: 171-175.
10. Bottex C., Cristau B., Corazza J.L. et al. Effect of two bacterial extracts, OM-89 and Broncho-Vaxom, on IL-1 release and metabolic activity of murine macrophage cell-line. Int. J. Immunotherapy 1988; 4: 203-212.
11. Bowman L.M., Holt P.G. Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect. Immun. 2001; 69: 3719-3727.
12. + immunostimulatory dendritic cells. Immunol. Lett. 2001; 76: 63-67.
13. Emmerich B., Emslander H.P., Pachmann K. et al. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 1990; 57: 90-99.
14. Djuric O., Mihailovic-Vucinic V., Stojcic V. Effect of Broncho -Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo -controlled study. Int. J. Immunother. 1989; 5: 139-143.
15. Misfeldt M.L. Evaluation of the immunomodulatory activities of LW 50020. Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, USA, Research Report, 1998.
16. van Daal G.J., Beusenberg F.D., So K.L. et al. Protection against influenza A virus infection in mice by oral immunization with a polyvalent bacterial lysate. Int. J. Immunopharmac. 1991; 7:831-840.
17. van Daal G.J., van't Veen A., So K.L. et al. Oral immunization with a polyvalent bacterial lysate and infection with Streptococcus pneumoniae: Influence on interferon gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluid. Int. Arch. Allergy Immunol. 1992; 97: 173-177.
18. Ruedl Ch., Kohler N., Wich G., Wolf H. Enhancement of the local immune response in the respiratory system by bacterial immunomodulators. Regional Immunology 1994; 6: 361-364.
19. van Abel A., Kämmereit A., Kulas H.P. Effects of Paspat oral on lymphocyte stimulation in healthy volunteers. Study No Fk-03/ /89, Research Report, Lustpold Pharma, Munich, 1990.
20. + lamina propria T cell in organ cultures of human colonic mucosa. Research Report, 1996.
21. Frühwirth M., Wick G., Wolf H. The increase of specific immune defense mechanisms in laboratory animals as a result of an oral administration of LW 50020B. University of Innsbruck, Austria; Research Report 1990; 9.
22. Ruedl Ch., Frühwirth M., Wick G., Wolf H. Immune response in the lungs following oral immunostimulation with bacterial lysates of respiratory pathogens. Clin. Diag. Lab. Immunol. 1994; 1: 150-154.
23. Stad R.H., Aubel van A., Abel S., Elsasser U. Development of immunocytochemical methods for Luivac tablets. Bio-Medical Consulting Group Toronto-Munich, Bowmanville, Ontario, Canada 1997.
24. Aubel van A., Elsasser U., Kämmereit A. et al. Immunoglobulins in serum and saliva of children with recurrent infections of the respiratory tract during treatment with an oral immunomodulator. In: Immunotherapy of Infections. Ed. Masihi K.N. Marcel Dekker, New York 1994; 357-369.
25. Frühwirth M., Wick G., Wolf H. Oral administrated bacterial vaccine induces increased sIgA levels in the human respiratory tracts. International symposium on mucosal immunity of the respiratory tract; abstract. Allergologie 1989; 7: 300.
26. Wichels R., Wolfschaffner F., Guggenbichler J.P. Prophylaxis of infections. Sonderdruck TW Pädiatric 1996; 9: 421-423.
27. Helmberg A, Böck G., Wolf H., Wick G. An orally administered bacterial immunomodulator primes rabbit neutrophils for increase oxidative burst in response to opsonized zymosan. Infect. And. Immun. 1989; 57: 3576-3580.
28. Ellenrieder M. Comparison of Luivac PPS and Luivac/F stimulation of phagocytosis in vitro. Sankyo Pharma, Munich, Research Report, 1997.
29. Bellanti J., Olivieri D., Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs 2003; 17: 355-367.
30. Bousquet J., Oliveri D. Role of ribomunyl((r)) in the prevention of recurrent respiratory tract infections in adults: overview of clinical results. Treat. Respir. Med. 2006; 5: 317-324.
31. Normier G., Pinel A.M., Dussourd D'Hinterland L. et al. NK-cell stimulating properties of a membrane proteoglycane from non-capsulated Klebsiella pneumoniae biotype a. APMIS 1985; 93: 233-243.
32. Faure G.C., Bene M.C., Simon C. et al. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int. J. Immunopharmacol. 1990; 12: 315-320.
33. Jongmans W., Tiemessen D.M., van Vlodrop I.J. et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J. Immunother. 2005; 28: 480-487.
34. Bystron J., Hermanova Z., Szotkovska J. et al. Effect of ribosomal immunotherapy on the clinical condition and plasma levels of cytokines IL-4, IL-5, IL-12 and IFN-gamma and total IgE in patients with seasonal allergy during the pollen season. Clin. Drug Invest. 2004; 24: 761-764.
35. Brunetti L., Francavilla R., Tesse R. et al. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome: a pilot study. BioDrugs 2005; 19: 393-399.
36. Sironi M., Sica A., Riganti F. et al. Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int. J. Immunopharmacol. 1990; 12: 397-402.
37. Luini W., De Rossi M., Licciardello L. et al. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int. J. Immunopharmacol. 1991; 13:631-637.
38. De Baets F., Kint J., Pauwels, Leroy J. IgG subclass deficiency in children with recurrent bronchitis. Eur. J. Pediatr. 1992; 151: 274-278.
39. Popa V., Kim K., Heiner D.C. IgG deficiency in adults with recurrent respiratory infections. Ann. Allergy 1993; 70: 418-424.
40. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 1991; 58:150-154.
41. Schaad U.B., Farine J.C., Fux T. Prospektive Plazebo-kontrollierte Doppelblindstudie mit einem Bakterienlysat bei Infektionen der Atemwege und des ORL-Bereiches im Kindesalter. Helv. Paediatr. Acta 1986; 41: 7-17.
42. Jara-Perez J.V., Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin. Ther. 2000; 22: 748-759.
43. Gutierrez-Taraugo M.D., Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 2001; 119:1742-1748.
44. Geiser G. Prevention des maladies respiratoires une grande enterprise industrielle: etude en double-aveugle du Broncho-Vaxom. Acta Ther. 1983; 9: 289-303.
45. Serrano E., Demanez J.P., Morgon A. et al. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double -blind placebo-controlled study. Eur. Arch. Otorhinolaryngol. 1997; 254: 372-375.
46. Heintz B., Schlenter W.W., Kirsten R. et al. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis: a multicentric, placebo-controlled, double-blind study. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27: 530-534.
47. Steurer-Stey C., Bachmann L.M., Steurer J., Tramèr M.R. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126: 1645-1655.
48. Orcel B., Delclaux B., Baud M. et al. Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients: preliminary results at six months in 291 patients. Rev. Mal. Respir. 1993; 10: 23-28.
49. Germouty J. Immunotherapy of recurrent respiratory infections: double-blind study of a new immunomodulator in 60 patients. Rev. Pneumol. Clin. 1986; 42: 207-213.
50. Cvoriscec B., Ustar M., Pardon R. et al. Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration 1989; 55: 129-135.
51. http://www.ompharma.ch/broncho-vaxom/mechanism -action.htm